Tricuspid / Pulmonary valve

The review aims to address the unmet needs in heart failure (HF) management, particularly in patients where structural heart disease coexists with HF and limits the effectiveness of guideline-directed medical therapy (GDMT).

Alex Sticchi provides his take on the results of the TRI.FR trial presented by Erwan Donal at the ESC Congress 2024 in London.

What was new and hot in interventional cardiology at #ESCCongress 2024!

Watch the replay of this webinar to get the main results from the TRI-FR trial, along with interventional and heart valve disease specialist interpretations based on the existing evidence!

The take-home message for clinicians is that in the treatment of tricuspid regurgitation, the most frequent valvular disease alongside aortic stenosis, redefining procedural success as a function of the residual degree of TR is crucial.

Alex Sticchi provides his take on the trials which were presented at New York Valves 2024, offering a concise summary, a short description and final thoughts. 

Watch the replay of this webinar to learn about secondary tricuspid regurgitation (TR) and management of TR in patients with cardiac implantable electronic devices (CIED) and much more!

In this EuroPCR 2024 session, explore a transcatheter edge-to-edge mitral valve repair case, delve into discussions backed by simulation, evidence, and real-world cases to understand atraumatic clasp and closure techniques and predictable implant release. Additionally, gain insights into real-world evidence for tricuspid TEER from the EuroTR trial...

This session provides updates on the latest developments in transcatheter mitral and tricuspid valve interventions. Key topics include one-year outcomes of the MiCLASP study on transcatheter mitral repair, the impact of residual mitral and tricuspid regurgitation after transcatheter repair, and the early feasibility of the AltaValve...